TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06136871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP Procedures
Description: CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Inactive Control Group
Description: An inactive control group will be used to control for maturation and testing effects. Weekly contact will be made via teleconferencing to (1) maintain study engagement, (2) introduce weekly social contact with researchers, mimicking some of the potential incidental effects of the experimental group, and (3) ascertain what, if any, additional steps participants have taken to reduce PCS symptoms. The content of each of these meetings will be tracked in intervention notes. Each contact will be recorded for fidelity monitoring to ensure all active ingredients of the CO-OP intervention are avoided.
Study: NCT05682170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5 ZN-c3
Description: Oral agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: Oral agent
Study: NCT05484102

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk fermented with lactobacillus paracasei CBA L74
Description: milk fermented with lactobacillus paracasei CBA L74 will be administered daily for 3 months to 100 children. Participants were supplied with the milk product in powder form, by Heinz Italia SpA, Segrate, Italy. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo milk formula
Description: placebo milk formula containing maltodextrins will be administered daily for 3 months to 100 children. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
Study: NCT05577754

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpelisib (BYL719)
Description: Administration during open label and double-blind period of group B: alpelisib will be taken once a day each day over 24 mois During open label period of group A: alpelisib will be taken once a day each day over 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib (BYL719)
Description: Administration during open label and double-blind period of group B: alpelisib will be taken once a day each day over 24 mois During open label period of group A: alpelisib will be taken once a day each day over 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: During double-blind period of group A: matching placebo will be taken once a day each day over 6 months

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Optional lumbar puncture + blood sample
Description: Between 6 and 24 months of treatment with Alpelisib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional lumbar puncture + blood sample
Description: Between 6 and 24 months of treatment with Alpelisib
Study: NCT06389526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHS-1000
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHS-1000
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Specified dose on specified days
Study: NCT06095986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aramchol meglumine
Description: Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aramchol meglumine
Description: Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)
Study: NCT04733326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: final rinse with non-steriodal anti-inflammatory drug during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: final rinse with cold saline during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: final rinse with saline at room temperature during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
Study: NCT04790188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nootropic
Description: 10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nootropic
Description: 10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10g of maltodextrin lemon flavor (HSN®).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10g of maltodextrin lemon flavor (HSN®).
Study: NCT05189275

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily Beverage Intervention
Description: Individuals will consume one of 4 beverages, daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily Beverage Intervention
Description: Individuals will consume one of 4 beverages, daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily Beverage Intervention
Description: Individuals will consume one of 4 beverages, daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Daily Beverage Intervention
Description: Individuals will consume one of 4 beverages, daily for 8 weeks.
Study: NCT06491186

Intervention type: OTHER
Intervention: Point of Care Ultrasound
Description: Point-of-care ultrasound will be used to image the femoral vessels and to assess the presence or absence of a pulse and the compressibility of the artery during rhythm checks.
Study: NCT05301959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low intensity percutaneous musculoskeletal electrolysis
Description: An acupuncture needle (0.30mm X 25mm) will be introduced into the device's strut. With the equipment on and with a base intensity of 120µA, the acupuncture needle is introduced in a proximal-distal and postero-anterior direction, in the area of the Achilles tendon body. The position of the needle will be checked with ultrasound and once the point to be treated is reached, the working intensity will be increased up to 600 µA. The emission will be maintained until the participant reports a pain of 60/100 in VAS. At that moment, the emission will be paused completely until the participant reports a sensation of at least 20/100 in VAS. After this period the emission will be continued at 600 µA. This cycle will continue until the emission lasts for more than 120 sec, continuously. At this point, the needle will be repositioned to repeat the emission protocol a maximum of 3 times in total.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham application
Description: A modification will be made in a second equipment, closing the circuit with a 10kΩ resistor inside the equipment, in the output strand chip. Allowing the simulation of emission without emitting current to the participant and without being able to appreciate any type of alteration in the handling of the equipment, by the operators. Therefore, the same steps will be followed as in the experimental group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silbernagel protocol
Description: The Silbernagel et al. protocol comprises several heel raising exercises with concentric and eccentric movements, performed on two legs and one leg. It is composed of 3 sets of 15 repetitions and that during the exercises allows pain to be present, but not being disabling. The exercises will be performed only once a day. The progression will be made by changing from standing exercises to monopodal support, moving from concentric-eccentric to purely eccentric loading, adding weight in a backpack (in steps of 5 kg when pain does not exceed 5 in the pain monitoring model) and finally using fast rebound exercises and plyometric exercises.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Silbernagel protocol
Description: The Silbernagel et al. protocol comprises several heel raising exercises with concentric and eccentric movements, performed on two legs and one leg. It is composed of 3 sets of 15 repetitions and that during the exercises allows pain to be present, but not being disabling. The exercises will be performed only once a day. The progression will be made by changing from standing exercises to monopodal support, moving from concentric-eccentric to purely eccentric loading, adding weight in a backpack (in steps of 5 kg when pain does not exceed 5 in the pain monitoring model) and finally using fast rebound exercises and plyometric exercises.
Study: NCT04696380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUUL e-cigarette
Description: Participants will sample preferred vs non-preferred JUUL flavors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUUL e-cigarette
Description: Participants will sample preferred vs non-preferred JUUL flavors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUUL e-cigarette
Description: Participants will sample preferred vs non-preferred JUUL flavors.
Study: NCT05182086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group physical therapy and dietary improvements
Description: 20 patients allocated to intervention group. During 12 weeks, patients will participate in a combined lifestyle intervention, including a one-hour physical therapist guided exercise group twice a week and consultation by a nutritional scientist. In case of inadequate intake, dietary supplements will be provided.
Study: NCT06374550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jump Start on the Go
Description: Centers will receive the Jump Start On The Go mental health program via a mobile app. This will entail receiving 12-24 mental health consultation sessions in which a licensed mental health consultant will use a mobile app that will provide directors and teachers with access to information such as videos, infographics, and an Artificial Intelligence Chatbot on how to work with children with challenging behaviors. Participants will receive the intervention once per week for up to 1 hour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Jump Start Plus Coronavirus Support
Description: The Jump Start Plus Coronavirus Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
Study: NCT06247124

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: multi-channel communication campaign to promote HPV vaccination
Description: High school students will develop, implement, and evaluate a multi-channel communication campaign to promote HPV vaccination.
Study: NCT05524025

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary TTMV-HPV DNA Test
Description: Mouthwash rinse

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary TTMV-HPV DNA Test
Description: Mouthwash rinse

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood TTMV-HPV DNA Test
Description: Blood test
Study: NCT05975255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Intravenous administration of predetermined dose of Byfavo for 30 seconds
Study: NCT04913454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40 Hz multi-sensory (auditory + visual) stimulation and cognitive training
Description: 40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)
Study: NCT06222099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heartfelt Device installed
Description: Device installed in the patient's home and capturing foot volume data which are processed in the cloud.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heartfelt Device installed
Description: Device installed in the patient's home and capturing foot volume data which are processed in the cloud.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heartfelt Device installed
Description: Device installed in the patient's home and capturing foot volume data which are processed in the cloud.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heartfelt Device installed
Description: Device installed in the patient's home and capturing foot volume data which are processed in the cloud.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Remote patient monitoring companies in regular contact with patients as per their standard operating procedures. (RPMC do not receive measurement data from the Heartfelt device, but will get any other data they collect via their usual methods e.g. remotely monitored weight data)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct-to-patient alerts
Description: The Heartfelt device sends alerts to the patients directly (audio-visual alert on the device, and app alerts).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct-to-patient alerts
Description: The Heartfelt device sends alerts to the patients directly (audio-visual alert on the device, and app alerts).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RPMC care
Description: The RPMC receives measurement data and alert data from the device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RPMC care
Description: The RPMC receives measurement data and alert data from the device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients were presented with one or more optional questionnaires (some validated, some bespoke)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients were presented with one or more optional questionnaires (some validated, some bespoke)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patients were presented with one or more optional questionnaires (some validated, some bespoke)
Study: NCT06521086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition Supplements - Fresubin KCAL Drinks
Description: Fresubin drinks will be taken up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
Study: NCT05562791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]PSMA
Description: 68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]PSMA
Description: 68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
Study: NCT05839015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Intervention Based on Self-Compassion
Description: Self-compassion techniques aim at developing compassionate skills for emotion regulation, such as self-kindness, recognition of common humanity, and mindfulness.
Study: NCT05562791

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Description: 68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Description: 68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
Study: NCT04934748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
Study: NCT05255679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early FES
Description: FES cycling starting 14-21 days post SCI for 6 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delayed FES
Description: FES cycling starting 3 months (+ 14-21 days) post SCI, for 3 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
Study: NCT05688059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absorbable Suture and Permanent Suture
Description: Absorbable Suture and Permanent Suture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absorbable Suture and Permanent Suture
Description: Absorbable Suture and Permanent Suture
Study: NCT05408338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Added Sugar Meal
Description: Consumption of a single 1,250 kcal meal containing 16 g of added sugars (5% of total energy)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Added Sugar Meal
Description: Consumption of a single 1,250 kcal meal containing 61 g of added sugars (20% of total energy)
Study: NCT05005260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Subjects randomized to the continuous interscalene nerve block group will receive a loading dose of 15-20 mL bupivacaine HCl 0.5% followed by a continuous catheter infusion of bupivacaine 0.2% at 8 mL per hour for 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj
Description: Subjects will receive a one-time interscalene nerve block injection of 5 mL of bupivacaine 0.5% (25 mg) admixed with 10 mL of liposomal bupivacaine (133 mg).
Study: NCT05602493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soludronate®
Description: In the first visit, the randomized process will take place. Tooth extraction procedure will be performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: sterile saline
Study: NCT06560203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Description: Neurointerventionist determine whether to proceed with interventional therapy after assessing the location and degree of occlusion, the tortuosity of the access vessel, and the presence of stenosis or occlusion in the proximal artery. In cases where there is no proximal stenosis or occlusion, mechanical thrombectomy is performed, and the specific thrombectomy strategy is tailored by the researcher based on the patient's condition. For lesions associated with proximal vascular stenosis or occlusion, it is necessary to navigate the catheter through the proximal stenosis or occlusion to access the intracranial occlusion. Researchers have the discretion to treat the stenotic or occluded vessels, which may include options such as no treatment, stent thrombectomy, thrombus aspiration, balloon angioplasty, stent replacement, intra-arterial thrombolysis or various combinations of these methods.
Study: NCT06035562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PVSET
Description: 6, one-hour sessions of individual therapy, consisting of Positive Valence System Enhancement Treatment for Anxiety and Depression (PVSET), which will consist of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.